Why is COIN stock down today? Coinbase earnings have investors spooked
Emotionally intelligent people use the 2-week rule to motivate themselves and reach their biggest goals
Exclusive: Google is indexing ChatGPT conversations, potentially exposing sensitive user data
Cinemark is opening 6 new panoramic, 270-degree movie theaters in 2025, and 14 more next year. Is one coming near you?
What happened?
Shares of Coinbase Global (Nasdaq: COIN) were down 15% in morning and midday trading on Friday, the lowest price the stock has hit in more than a month, after it reported lower-than-expected second-quarter adjusted profit due to a slowdown in trading, according to Reuters.
Coinbase earnings
Revenue came in at $1.5 billion, which missed analyst expectations of $1.6 billion, while revenue tied to transactions came in at $764 million, missing StreetAccount estimates of $787 million, according to CNBC.
However, other earnings numbers came in strong.
In the three months ending June 30, Coinbase's net income rose to $1.43 billion, delivering earnings per share (EPS) of $5.14. A further look at Coinbase's EPS shows the company beat analyst expectations of $1.51 by $3.63.
Subscriptions and services offerings—which include stablecoins, staking, interest income, and custody—grew 9% from the same period a year ago, to $655.8 million, short of analysts' projection of $705.9 million.
Analysts told Reuters that Coinbase could see trading volume improve, according to the company's revenue estimates.
The earnings follow a surge in crypto spurred on by the GENIUS Act being signed into law on July 18.
Coinbase on S&P 500
Coinbase joined the S&P 500 stock market index in May, replacing Discover; it is the first time a crypto company has been included on the index. The S&P 500 is one of the world's best-known stock market indexes.
This post originally appeared at fastcompany.comSubscribe to get the Fast Company newsletter: http://fastcompany.com/newsletters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Sibanye Stillwater Limited (SBSW): A Bull Case Theory
We came across a bullish thesis on Sibanye Stillwater Limited on by walter99. In this article, we will summarize the bulls' thesis on SBSW. Sibanye Stillwater Limited's share was trading at $9.24 as of July 25th. SBSW's trailing and forward P/E were 4.67 and 10.94, respectively according to Yahoo Finance. A mine entrance, showcasing the precious metals and minerals that this company produces. Sibanye-Stillwater (SBSW), a major producer of platinum group metals (PGMs)—platinum, palladium, and rhodium—offers a leveraged play on a sector where years of underinvestment and misjudged demand forecasts have created the setup for an extended upcycle. PGMs are essential for automotive catalysts and jewelry, with catalytic converters alone accounting for 43% of platinum and 84% of palladium demand. Market pessimism has been fueled by overestimates of battery electric vehicle (BEV) penetration, but BEV sales growth in the U.S. and Europe flatlined in 2024, suggesting that internal combustion engine and hybrid vehicle demand—and thus PGM demand—will remain resilient. Supply is structurally constrained: South African PGM miners underspent by ~$18 billion over the last decade, 40% of global supply operates at or below cash costs, and production is forecast to decline through 2029. With long lead times for new supply, a persistent deficit projected by the World Platinum Investment Council, and palladium in deficit until at least 2028, any uptick in demand can drive a sharp price response. Recycling, a secondary supply source, remains depressed post-COVID, adding to market tightness. SBSW's profits, crushed by low PGM prices in 2024, have substantial torque to higher prices, as shown in 2020–2021 when the stock hit $20 on elevated metal prices. Today, at $7, platinum's rebound to $1,250 suggests early signs of a cyclical turn. Risks include economic weakness, faster BEV adoption, and rising recycling supply, but with constrained production, a decade of underinvestment, and platinum already rallying, SBSW presents asymmetric upside if PGM prices sustain an upcycle. Previously, we covered a on Sibanye Stillwater Limited (SBSW) by Hugo Navarro in February 2025, highlighting its diversified asset base in PGMs, gold, lithium, and recycling, with growth levers despite weak PGM prices. The stock has appreciated by about 130% as PGM prices rebounded. The thesis still stands, and Walter99 shares a similar view but emphasizes SBSW's leverage to a sustained PGM upcycle. Sibanye Stillwater Limited is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 20 hedge fund portfolios held SBSW at the end of the first quarter which was 18 in the previous quarter. While we acknowledge the potential of SBSW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy. The stock initially surged on the news, but then reversed course and is currently trading down approximately 9%. The central nervous system (CNS) disorders-focused company said the topline results from the Phase 2 RADIANT study included data from 37 patients.'These findings build on our earlier clinical data showing a differentiated profile for vormatrigine as a fast-acting, no-titration, once-daily oral drug with no requirement to be taken with food, and a favorable DDI profile, all of which are unseen in ASMs currently in the market or in development,' said Marcio Souza, president and CEO of Praxis. In an investor presentation on the company website, Praxis noted that the trial showed a median seizure reduction of around 56.3%, with 60% of the patients achieving at least a 50% reduction in seizures. This positive outcome has encouraged the company to move forward with a Phase 2/3 trial, even though 23% of patients discontinued the study. 54% of patients achieved at least a 50% seizure reduction threshold in Week 1 and 67% in Week 8. In the last month of the dataset, 22% of the patients experienced a 100% reduction in seizure frequency. The company added that most adverse events were mild to moderate and transient. All severe and serious adverse events (AEs) were recovered and resolved. The investor presentation noted that the investigators had the option to reduce the dose of the background medication to manage AEs; when done (6 patients), no discontinuation was observed. The company said it is on track to complete the pivotal, 12-week POWER1 study in the fourth quarter of 2025 and, based on the results from RADIANT, it expects to initiate the POWER2 study shortly. On Monday, the company reported cash and investments of approximately $447 million and maintains a cash runway into 2028. In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Praxis Precision's relutrigine, a sodium channel functional state modulator for pediatric use for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The EMBOLD cohort 2 pivotal trial is on track for topline results in the first half of 2026, with NDA filing to follow. Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs. Price Action: PRAX stock is trading lower by 9.51% to $48.95 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
5 minutes ago
- Yahoo
Palantir is set to report second quarter earnings after announcing $10 billion US Army deal
Palantir (PLTR) was set to report quarterly earnings Monday after the bell, with Wall Street expecting another period of double-digit growth for the defense tech firm. Wall Street analysts tracked by Bloomberg expect the company to report second quarter adjusted earnings per share of $0.14, up from $0.09 the prior year. They expect revenue to hit $939.25 billion, up roughly 39% from last year, according to Bloomberg data. 'Expectations for Palantir headed into earnings are as high as ever,' DA Davidson analyst Gil Luria told Yahoo Finance in an email. 'The company has easily exceeded expectations for several recent quarters and appears to have more momentum than any other publicly traded software company.' Read more: Live coverage of corporate earnings Palantir sells its artificial intelligence software to businesses and governments in the US and abroad. Its tech does everything from supply chain analysis to surveillance and identifying military targets, the latter of which has drawn backlash from human rights advocates. In May, Palantir stock fell 12% the day after its first quarter results as investors scrutinized the company's valuation and declining sales in its international commercial business, which sells software to businesses abroad, even as its first quarter revenue blew past Wall Street's forecasts. While analysts expect revenue from sales to governments and US businesses to continue soaring in the second quarter, they see sales in its international commercial segment declining slightly to about $147.1 billion from $148 billion last year. Boosting optimism for the future of its revenue from the US government, Palantir announced Thursday that it had inked a deal with the US Army worth up to $10 billion over the next 10 years. Wedbush analyst Dan Ives, a notable Palantir bull, said the deal is 'one of the largest ever DOD [Department of Defense] software contracts in US history.' 'We believe this deal represents an additional tailwind for PLTR with AI initiatives across the US government accelerating with AI a strategic focus on the federal front and Palantir in the sweet spot to benefit from a tidal wave of federal spending on AI,' Ives wrote in a note to investors Friday. Overall, Wall Street remains mixed on Palantir stock, however. Ives is one of 10 analysts who hold a Buy rating on shares, while 16 have a Hold rating, and five recommend selling the stock, according to Bloomberg data. Bears remain concerned that Palantir is overvalued. Palantir stock currently trades at levels 24 times the historical market multiple of the S&P 500 (^GSPC). Shares of Palantir are up more than 105% this year, relative to the S&P 500's 6.3% gain, and the stock has far outperformed the "Magnificent Seven" Big Tech stocks in 2025. 'We cannot rationalize why Palantir is the most expensive name in our software coverage,' RBC Capital Markets analyst Rishi Jaluria wrote in a note to clients Wednesday. 'Absent a substantial beat-and-raise quarter elevating the NT [near term] growth trajectory, valuation seems unsustainable.' A 'beat and raise' refers to a company's earnings surpassing Wall Street's expectations and raising its financial outlook for the upcoming Bratton is a reporter for Yahoo Finance. Follow her on Bluesky @ Email her at
